Julie R. Brahmer, MD
There may be potential for immunotherapy in lung cancer beyond PD-1/PD-L1 and CTLA-4 inhibitors, said Julie R. Brahmer, MD, but first, researchers need to gain a better understanding of resistance mechanisms or lack of response in these patients, which will ultimately lead to a more precision medicine approach.
However, there has been recent progress in difficult-to-treat populations. For example, in small cell lung cancer (SCLC), a disease for which the treatment paradigm has remained stagnant for almost 20 years, PD-L1 inhibitors are starting to make headway. Results from the phase III IMpower133 trial demonstrated a survival advantage with the addition of frontline atezolizumab (Tecentriq) to chemotherapy with carboplatin and etoposide in patients with extensive-stage SCLC versus chemotherapy alone.1
... to read the full story